Creative Medical Technology Holdings, Inc. CELZ
Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026
Creative Medical Technology Holdings, Inc. (CELZ) is a healthcare company listed in the US with a market value of about $4M. In the twelve months to September 30, 2026 it had revenue of $3000 and net income of -$7M, a net margin of -249160.1%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -48% a year, a 5-year average ROIC of -64%.
About Creative Medical Technology
Creative Medical Technology is listed in the US and classified in biotechnology: biological products (no diagnostic substances). Revenue went from $4800 in 2017 to $6000 in 2025, growth of about 2.8% a year. It was profitable in 1 of the last 10 years in our data. Its share count fell by 78% over three years (buybacks). It spends 37663% of revenue on research and development.
Score: 1.2 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
- Share count down over 3 years (buybacks)
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3000 | $6000 | $11000 | $9000 | $88600 | — | $164500 | $165500 | $124400 | $4800 | $0 |
| Net income | -$7M | -$6M | -$5M | -$5M | -$10M | $19M | -$36M | -$8M | -$14M | -$3M | -$766072 |
| Free cash flow | -$7M | — | — | — | — | — | -$434556 | -$1M | -$1M | -$889621 | -$445232 |
| EPS (diluted) | $-1.99 | $-2.52 | $-3.71 | $-3.76 | $-0.93 | $5.61 | $-62.69 | $-0.82 | $-3.50 | $-4.50 | $-1.50 |
| Net margin | -249160.1% | -99916.8% | -49940.7% | -58739.7% | -11449.3% | — | -22082.2% | -5126.1% | -10977.2% | -55398.1% | — |
| ROIC | — | -81.7% | -90.6% | -54.3% | -64.6% | -30.6% | — | — | — | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 1 analysts is $20.00, 3687% above the current price; targets range from $20.00 to $20.00; the consensus rating is “Strong buy”; expected EPS is $-1.56 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Creative Medical Technology pay a dividend?
Not currently.
Is Creative Medical Technology a good stock to buy?
We do not give buy or sell advice. Creative Medical Technology scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.